We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Outlook Therapeutics to Report Q3 Earnings: What's in the Cards?
Read MoreHide Full Article
Key Takeaways
Outlook Therapeutics awaits Q3 results as Lytenava sales and commercialization remain in focus.
OTLK secured FDA approval for Lytenava in late July and plans a U.S. launch by year-end.
OTLK is expected to post a loss while investing in U.S. launch, reimbursement and commercial efforts.
We expect Outlook Therapeutics (OTLK - Free Report) to beat expectations when it reports third-quarter fiscal 2026 results later this month. In the last reported quarter, the company delivered a negative earnings surprise of 33.33%.
The Zacks Consensus Estimate for revenues is pegged at $1.20 million, while the same for earnings is pinned at a loss of 9 cents per share.
Let us see how things might have shaped up for OTLK in the soon-to-be-reported quarter.
Factors Likely to Influence OTLK’s Q3 Results
Being a single-asset biotechnology company, Outlook Therapeutics’ growth is entirely centered on its sole product, Lytenava, approved for the treatment of patients with wet age-related macular degeneration (wet AMD). The drug has been commercialized across the European Union and the United Kingdom since 2024.
The most significant milestone during the quarter was the U.S. approval of Lytenava in late July for the said indication, ahead of schedule. The approval followed the successful resubmission of the biologics license application in June after the company resolved issues raised in the FDA's complete response letter in December 2025. The company expects to launch the product in the United States by the end of this year.
Over the past few quarters, Outlook Therapeutics has generated modest revenues from sales of the drug in ex-U.S. markets, with investors expecting stronger commercial momentum ahead of the planned U.S. launch.
OTLK is likely to have continued incurring losses in the to-be-reported quarter as it invests in U.S. commercial infrastructure and launch activities. However, investors will be looking for sequential improvement in European product sales, with Lytenava already launched in selected markets, as management previously noted a recovery in unit sales following an initial slowdown.
Beyond quarterly financial performance, the earnings call is expected to provide important updates on the timing of the U.S. commercial rollout, inventory availability, reimbursement progress and management's expectations for revenue generation during the remainder of fiscal 2026.
Outlook Therapeutics has a dismal history of earnings surprises. The company’s earnings missed estimates in three of the trailing four quarters, while beating the same on the remaining occasion, delivering an average negative surprise of 15.79%.
OTLK’s Stock Performance
Year to date, shares of Outlook Therapeutics have lost 38.2% against the industry’s 2.7% growth.
Image Source: Zacks Investment Research
Earnings Whispers for OTLK
Our proven model predicts an earnings beat for OTLK this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is the case here, as you will see below. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Earnings ESP: Outlook Therapeutics has an Earnings ESP of +42.31% as the Most Accurate Estimate currently stands at a loss of 5 cents and the Zacks Consensus Estimate of loss is pegged at 9 cents.
Here are a few other stocks worth considering from the healthcare space, as our model shows that these too have the right combination of elements to beat on earnings this reporting cycle.
Harmony Biosciences (HRMY - Free Report) has an Earnings ESP of +14.14% and a Zacks Rank #1 at present.
Shares of HRMY have lost 5.6% over the past six months. The company’s earnings missed estimates in each of the trailing four quarters, delivering a negative average surprise of 25.16%.
ACADIA Pharmaceuticals (ACAD - Free Report) has an Earnings ESP of +25.00% and a Zacks Rank #2 at present.
Shares of ACAD have risen 6.8% over the past six months. The company’s earnings beat estimates in three of the trailing four quarters but missed in the remaining quarter, delivering an average surprise of 20.83%.
Arcutis Biotherapeutics (ARQT - Free Report) has an Earnings ESP of +52.94% and a Zacks Rank #2 at present.
Shares of ARQT have risen 3% over the past six months. The company’s earnings beat estimates in three of the trailing four quarters but missed in the remaining quarter, delivering an average surprise of 42.78%. ARQT is scheduled to report second-quarter results on Aug. 5.
View the Zacks #1 Rank List
Image: Bigstock
Outlook Therapeutics to Report Q3 Earnings: What's in the Cards?
Key Takeaways
We expect Outlook Therapeutics (OTLK - Free Report) to beat expectations when it reports third-quarter fiscal 2026 results later this month. In the last reported quarter, the company delivered a negative earnings surprise of 33.33%.
The Zacks Consensus Estimate for revenues is pegged at $1.20 million, while the same for earnings is pinned at a loss of 9 cents per share.
Let us see how things might have shaped up for OTLK in the soon-to-be-reported quarter.
Factors Likely to Influence OTLK’s Q3 Results
Being a single-asset biotechnology company, Outlook Therapeutics’ growth is entirely centered on its sole product, Lytenava, approved for the treatment of patients with wet age-related macular degeneration (wet AMD). The drug has been commercialized across the European Union and the United Kingdom since 2024.
The most significant milestone during the quarter was the U.S. approval of Lytenava in late July for the said indication, ahead of schedule. The approval followed the successful resubmission of the biologics license application in June after the company resolved issues raised in the FDA's complete response letter in December 2025. The company expects to launch the product in the United States by the end of this year.
Over the past few quarters, Outlook Therapeutics has generated modest revenues from sales of the drug in ex-U.S. markets, with investors expecting stronger commercial momentum ahead of the planned U.S. launch.
OTLK is likely to have continued incurring losses in the to-be-reported quarter as it invests in U.S. commercial infrastructure and launch activities. However, investors will be looking for sequential improvement in European product sales, with Lytenava already launched in selected markets, as management previously noted a recovery in unit sales following an initial slowdown.
Beyond quarterly financial performance, the earnings call is expected to provide important updates on the timing of the U.S. commercial rollout, inventory availability, reimbursement progress and management's expectations for revenue generation during the remainder of fiscal 2026.
Outlook Therapeutics, Inc. Price and Consensus
Outlook Therapeutics, Inc. price-consensus-chart | Outlook Therapeutics, Inc. Quote
Earnings Surprise History
Outlook Therapeutics has a dismal history of earnings surprises. The company’s earnings missed estimates in three of the trailing four quarters, while beating the same on the remaining occasion, delivering an average negative surprise of 15.79%.
OTLK’s Stock Performance
Year to date, shares of Outlook Therapeutics have lost 38.2% against the industry’s 2.7% growth.
Image Source: Zacks Investment Research
Earnings Whispers for OTLK
Our proven model predicts an earnings beat for OTLK this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is the case here, as you will see below. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Earnings ESP: Outlook Therapeutics has an Earnings ESP of +42.31% as the Most Accurate Estimate currently stands at a loss of 5 cents and the Zacks Consensus Estimate of loss is pegged at 9 cents.
Zacks Rank: Outlook Therapeutics currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Other Stocks to Consider
Here are a few other stocks worth considering from the healthcare space, as our model shows that these too have the right combination of elements to beat on earnings this reporting cycle.
Harmony Biosciences (HRMY - Free Report) has an Earnings ESP of +14.14% and a Zacks Rank #1 at present.
Shares of HRMY have lost 5.6% over the past six months. The company’s earnings missed estimates in each of the trailing four quarters, delivering a negative average surprise of 25.16%.
ACADIA Pharmaceuticals (ACAD - Free Report) has an Earnings ESP of +25.00% and a Zacks Rank #2 at present.
Shares of ACAD have risen 6.8% over the past six months. The company’s earnings beat estimates in three of the trailing four quarters but missed in the remaining quarter, delivering an average surprise of 20.83%.
Arcutis Biotherapeutics (ARQT - Free Report) has an Earnings ESP of +52.94% and a Zacks Rank #2 at present.
Shares of ARQT have risen 3% over the past six months. The company’s earnings beat estimates in three of the trailing four quarters but missed in the remaining quarter, delivering an average surprise of 42.78%. ARQT is scheduled to report second-quarter results on Aug. 5.